Immune intervention therapy in type 1 diabetes: safety first
- PMID: 24622405
- DOI: 10.1016/S2213-8587(13)70124-4
Immune intervention therapy in type 1 diabetes: safety first
Comment on
-
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8. Lancet Diabetes Endocrinol. 2013. PMID: 24622415 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical